SUPPLEMENT

Q4 2021 — Reconciliation of Non-GAAP Financial Measures

Q4 2021PDF · 6 pages193 KB
Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 	2021 	2020 	2021 	2020
Net Earnings, after tax- as reported 	$4,736 	$1,738 	$20,878 	$14,714
Pre-tax Adjustments
Intangible Asset Amortization expense 	1,121 	1,234 	4,697 	4,660
Litigation expense, net 	274 	2,902 	2,328 	5,112
IPR&D 	- 	37 	900 	181
Restructuring related 	140 	85 	473 	448
Acquisition, integration and divestiture related ¹ 	26 	14 	(478) 	(1,073)
(Gains)/losses on securities 	(198) 	(373) 	(533) 	(547)
Medical Device Regulation 	73 	55 	234 	144
Consumer Health separation costs 	67 	- 	67 	-
Other 	- 	- 	- 	6
Tax Adjustments
Tax impact on special item adjustments 2 	(184) 	(606) 	(1,281) 	(1,608)
Tax legislation and other tax related 	(377) 	(121) 	(1,090) 	(604)
Adjusted Net Earnings, after tax 	$5,678 	$4,965 	$26,195 	$21,433
Average shares outstanding (Diluted) 	2,670.2 	2,669.2 	2,674.0 	2,670.7
Adjusted net earnings per share (Diluted) 	$2.13 	$1.86 	$9.80 	$8.03
Operational adjusted net earnings per share (Diluted) 	$2.18 	$9.65
Notes:
1
2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the
above pre-tax special items in arriving at adjusted earnings.
Fourth Quarter 	Twelve Months Ended
Acquisition, integration and divestiture related for 2021 primarily includes the gain on the divestiture of two
Pharmaceutical brands outside of the U.S. Acquisition, integration and divestiture related for 2020 primarily includes a
Contingent Consideration reversal of $1,148M related to the timing of certain developmental milestones associated
with the Auris Health acquisition.

-- 1 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	1.1% 	16.5% 	4.1% 	10.4%
U.S. 	1.3% 	4.2% 	1.0% 	3.0%
International 	0.9% 	33.4% 	7.0% 	18.5%
WW Currency 	(0.7) 	(1.4) 	(1.2) 	(1.2)
U.S. 	- 	- 	- 	-
International 	(1.2) 	(3.5) 	(2.3) 	(2.7)
WW Operational 	1.8% 	17.9% 	5.3% 	11.6%
U.S. 	1.3% 	4.2% 	1.0% 	3.0%
International 	2.1% 	36.9% 	9.3% 	21.2%
General Surgery
Advanced Sterilization Products 	0.3 	0.1
U.S. 	0.0 	0.0
International 	0.5 	0.2
Skin Health / Beauty
Dr. Ci Labo - Sedona 	0.7 	0.1
U.S. 	0.0 	0.0
International 	1.2 	0.3
All Other Acquisitions and Divestitures 	0.4 	0.7 	0.1 	0.4
U.S. 	0.6 	0.0 	0.2 	0.1
International 	0.3 	1.7 	0.0 	0.8
WW Adjusted Operational 	2.9% 	18.6% 	5.6% 	12.3%
U.S. 	1.9% 	4.2% 	1.2% 	3.1%
International 	3.6% 	38.6% 	9.8% 	22.4%
Adjusted Operational Sales Growth
FOURTH QUARTER 2021 ACTUAL vs. 2020 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 2 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Consumer Health 	Pharmaceutical 	Medical Devices 	Total
WW As Reported 	4.1% 	14.3% 	17.9% 	13.6%
U.S. 	2.4% 	8.6% 	14.9% 	9.3%
International 	5.6% 	21.6% 	20.6% 	18.2%
WW Currency 	1.3 	1.2 	1.7 	1.4
U.S. 	- 	- 	- 	-
International 	2.5 	2.8 	3.3 	2.9
WW Operational 	2.8% 	13.1% 	16.2% 	12.2%
U.S. 	2.4% 	8.6% 	14.9% 	9.3%
International 	3.1% 	18.8% 	17.3% 	15.3%
General Surgery
Advanced Sterilization Products 	0.5 	0.1
U.S. 	0.0 	0.0
International 	1.0 	0.3
Skin Health / Beauty
Dr. Ci Labo - Sedona 	0.5 	0.1
U.S. 	0.0 	0.0
International 	1.0 	0.2
All Other Acquisitions and Divestitures 	0.4 	0.5 	0.1 	0.4
U.S. 	0.6 	0.0 	0.4 	0.2
International 	0.3 	1.4 	0.0 	0.8
WW Adjusted Operational 	3.8% 	13.6% 	16.8% 	12.8%
U.S. 	3.0% 	8.6% 	15.3% 	9.5%
International 	4.4% 	20.2% 	18.3% 	16.6%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
TWELVE MONTHS 2021 ACTUAL vs. 2020 ACTUAL
Segments

-- 3 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020
Reported Income/(loss) Before Tax by Segment 	$ 	338 	(2,057) 	4,343 	3,675 	575 	363 	(420) 	(334) 	4,836 	1,647
% to Sales 	9.2% 	-56.9% 	30.4% 	30.0% 	8.4% 	5.5% 	-1.7% 	-1.5% 	19.5% 	7.3%
Intangible asset amortization expense 	100 	109 	761 	868 	260 	257 	- 	- 	1,121 	1,234
In-process research and development 	- 	- 	- 	10 	- 	27 	- 	- 	- 	37
Litigation related 	122 	2,762 	(35) 	(172) 	187 	312 	- 	- 	274 	2,902
Loss/(gain) on securities 	1 	- 	(237) 	(368) 	38 	(5) 	- 	- 	(198) 	(373)
Restructuring related 	28 	(1) 	22 	24 	90 	62 	- 	- 	140 	85
Acquisition, integration and divestiture related 	- 	- 	5 	- 	21 	14 	- 	- 	26 	14
Medical Device Regulation 	- 	- 	- 	- 	73 	55 	- 	- 	73 	55
Consumer Health separation costs 	67 	- 	- 	- 	- 	- 	- 	- 	67 	-
Other 	- 	- 	- 	- 	- 	- 	- 	- 	- 	-
Adjusted Income Before Tax by Segment 	$ 	656 	813 	4,859 	4,037 	1,244 	1,085 	(420) 	(334) 	6,339 	5,601
% to Sales 	17.9% 	22.5% 	34.0% 	32.9% 	18.1% 	16.5% 	-1.7% 	-1.5% 	25.6% 	24.9%
*Estimated as of 1/25/2022
Q4 QTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 4 of 6 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020 	2021 	2020
Reported Income/(Loss) Before Tax by Segment 	$ 	1,294 	(1,064) 	18,181 	15,462 	4,373 	3,044 	(1,072) 	(945) 	22,776 	16,497
% to Sales 	8.8% 	-7.6% 	34.9% 	33.9% 	16.2% 	13.3% 	-1.1% 	-1.1% 	24.3% 	20.0%
Intangible asset amortization expense 	414 	415 	3,258 	3,246 	1,025 	999 	- 	- 	4,697 	4,660
In-process research and development 	- 	10 	900 	171 	- 	- 	900 	181
Litigation related 	1,603 	3,931 	640 	834 	85 	347 	- 	- 	2,328 	5,112
Loss/(gain) on securities 	(18) 	- 	(486) 	(545) 	(29) 	(2) 	- 	- 	(533) 	(547)
Restructuring related 	119 	68 	76 	94 	278 	286 	- 	- 	473 	448
Acquisition, integration and divestiture related 	- 	(562) 	20 	84 	(1,093) 	- 	- 	(478) 	(1,073)
Medical Device Regulation 	- 	- 	- 	234 	144 	- 	- 	234 	144
-
Consumer Health separation costs 	67 	- 	- 	- 	- 	- 	- 	67 	-
Other 	- 	- 	- 	- 	- 	6 	- 	- 	- 	6
Adjusted Income Before Tax by Segment 	$ 	3,479 	3,350 	21,107 	19,121 	6,950 	3,902 	(1,072) 	(945) 	30,464 	25,428
% to Sales 	23.8% 	23.8% 	40.5% 	42.0% 	25.7% 	17.0% 	-1.1% 	-1.1% 	32.5% 	30.8%
*Estimated as of 1/25/2022
Q4 YTD - Income Before Tax by Segment*
Dollars in Millions
Consumer Health 	Pharmaceutical 	Medical Devices 	Unallocated 	Worldwide Total

-- 5 of 6 --

Fourth Quarter 	Fourth Quarter
Jan. 2, 2022
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Medical Device
Regulation 	Other
Jan. 2, 2022
Non-GAAP
Cost of products sold 	7,955	$ 	(1,111) 	(21) 	(26) 	6,797
Selling, marketing and admin expenses 	7,154 	(7) 	7,147
Research and development expense 	4,720 	- 	(40) 	4,680
Other (Income) / Expense 	9 	(10) 	(274) 	(36) 	(26) 	198 	(67) 	- 	(206)
In-process research and development 	- 	- 	-
Restructuring 	83 	(83) 	-
Provision for taxes on income 	100 	162 	49 	- 	27 	6 	(89) 	14 	15 	377 	- 	661
Net Earnings 	4,736 	959 	225 	- 	113 	20 	(109) 	59 	52 	(377) 	- 	5,678
Fourth Quarter 	Fourth Quarter
Jan. 3, 2021
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Medical Device
Regulation 	Other
Jan. 3, 2021
Non-GAAP
Cost of products sold 	7,814	$ 	(1,225) 	(20) 	(19) 	6,550
Selling, marketing and admin expenses 	6,457 	(7) 	6,450
Research and development expense 	4,032 	- 	(29) 	4,003
Other (Income) / Expense 	2,354 	(9) 	(2,902) 	(5) 	(14) 	373 	- 	(203)
In-process research and development 	37 	(37) 	-
Restructuring 	60 	(60) 	-
Provision for/(Benefit from) taxes on income 	(91) 	(46) 	682 	6 	16 	3 	(66) 	11 	- 	121 	- 	636
Net Earnings 	1,738 	1,280 	2,220 	31 	69 	11 	(307) 	44 	- 	(121) 	- 	4,965
Twelve Months 	Twelve Months
Jan. 2, 2022
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Medical Device
Regulation 	Other
Jan. 2, 2022
Non-GAAP
Cost of products sold 	29,855	$ 	(4,661) 	(86) 	(85) 	25,023
Selling, marketing and admin expenses 	24,659 	(24) 	24,635
Research and development expense 	14,714 	(125) 	14,589
Other (Income) / Expense 	489 	(36) 	(2,328) 	(135) 	478 	533 	(67) 	- 	(1,066)
In-process research and development 	900 	(900) 	-
Restructuring 	252 	(252) 	-
Provision for taxes on income 	1,898 	667 	481 	202 	86 	(98) 	(116) 	44 	15 	1,090 	- 	4,269
Net Earnings 	20,878 	4,030 	1,847 	698 	387 	(380) 	(417) 	190 	52 	(1,090) 	- 	26,195
Twelve Months 	Twelve Months
Jan. 3, 2021
GAAP
Intangible asset
amortization
Litigation
expense, net
Restructuring
related
Medical Device
Regulation 	Other
Jan. 3, 2021
Non-GAAP
Cost of products sold 	28,427	$ 	(4,651) 	(89) 	(59) 	23,628
Selling, marketing and admin expenses 	22,084 	(17) 	22,067
Research and development expense 	12,159 	(68) 	12,091
Other (Income) / Expense 	2,899 	(9) 	(5,112) 	(112) 	1,073 	547 	(6) 	(720)
In-process research and development 	181 	(181) 	-
Restructuring 	247 	(247) 	-
Provision for taxes on income 	1,783 	504 	1,055 	36 	81 	13 	(108) 	27 	- 	604 	- 	3,995
Net Earnings 	14,714 	4,156 	4,057 	145 	367 	(1,086) 	(439) 	117 	- 	(604) 	6 	21,433
(1) 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States. 2020 primarily includes a Contingent Consideration reversal of $1,148M related to the timing of certain developmental milestones associated with the Auris Health acquisition.
Year to Date
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date
In-process
research and
development
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
Consumer Health
separation costs
Tax legislation and
other tax related
In-process
research and
development
Acquisition, integration and
divestiture related
(Loss)/gain on
securities
Consumer Health
separation costs
Tax legislation and
other tax related
In-process
research and
development
Acquisition, integration and
divestiture related (1)
(Loss)/gain on
securities
Consumer Health
separation costs
Tax legislation and
other tax related
In-process
research and
development
Acquisition, integration and
divestiture related (1)
(Loss)/gain on
securities
Consumer Health
separation costs
Tax legislation and
other tax related

-- 6 of 6 --